November 12, 2014
12:00 - 1:00 p.m.
B-369 Rayburn House Office Building
Registration: Please RSVP to Megan Anderson Brooks at email@example.com or 202.484.1100 by November 11, 2014.
Please join the Association for Molecular Pathology for a Congressional briefing highlighting the valuable role laboratory developed procedures (LDPs) play in precision medicine. Today, molecular (or genetic) based diagnostic tests enable physicians to tailor treatments for patients, reduce the likelihood of side effects, identify the causes of a disease, determine prognosis for cancer, and predict a person’s risk for developing a disease. LDPs are revolutionizing the way medicine is practiced and we’re only at the cusp of the possibilities. More, now than ever, it’s crucial to continue the investment in this emerging field and promote policies that will help realize the dream of precision medicine for all patients.
It is estimated that there are tens of thousands of LDPs in existence today used by as many as 11,000 labs across the United States. These specialized testing services play an essential role in medical decision-making by informing the diagnosis and care of patients. In October, the FDA issued a draft guidance indicating that the agency plans to begin regulating all LDPs, which it refers to as laboratory developed tests (LDTs). If the guidance is finalized, over the course of nine years, many labs will have to submit applications for premarket review for thousands of high and moderate risk LDPs if they wish to continue offering them to patients. Molecular pathologists are not manufacturers and complying with this proposed policy will not only drain their limited resources devoted to patient care, but also potentially subject them to the medical device tax, FDA user fees, product liability laws, and more. Of even greater concern, the FDA proposed policy could potentially stifle innovation by not allowing modifications to already approved or cleared LDPs, essentially freezing those tests in time.
On November 12th at 12 PM in B-369 Rayburn, please join AMP for a briefing to learn about how professionals in molecular pathology develop, validate, improve, and interpret LDPs, the proposed FDA framework for regulating LDPs, and its implications for patients, physicians, and the healthcare system.
This event complies with ethics and gift rules.